RESPONSIBLE

Conduct of Research

Our mission is to advance high-quality research and scholarship at UD by promoting an environment that fosters creativity, collaboration, community, and commitment to the highest ethical values.

Research Overview

University policy and federal law (45 CFR 46) require that all research involving human subjects, bio specimens and/or tissue samples from humans, and/or private identifiable data must be reviewed by an Institutional Review Board (IRB).

The University of Delaware (UD) requires that ALL research activities involving human subjects, bio specimens and/or tissue samples from humans, and/or private identifiable data be reviewed and approved by the IRB prior to their start. All submissions to the UD IRB must be made using IRBNet. Depending on the research proposed the IRB may issue different types of review as prescribed in the pertinent regulations and policies.

Submission of research protocols to the UD IRB must be completed in IRBNet. Please see the “IRBNET Submission Instructions” below for the step by step process.

IRBNET Submission Instructions

To Register as an IRBNet user and log in for the first time
  1. Go to http://www.irbnet.org
  2. In upper right-hand corner of the screen, under the log-in boxes, click on New User Registration and complete the registration (fill in your first and last name, create a user name and a password). Then click continue. On the next screen about Terms of Use, click ‘ACCEPT’
  3. In the box ‘Search for Organization’, type University of Delaware (make sure Research Institutions is selected) and then click the Search button. In the search results, select University of Delaware, Newark, DE and click Continue. Complete the required fields and click Continue. (Red * indicates required fields). Verify that all information is correct and click the Register button affiliating with the University of Delaware IRB. At the Registration is complete screen, click Continue
  4. Next, you will receive an email from IRBNet with the subject Activation Required
  5. Click on (or copy and paste) the IRBNet the link in the your email message to return to the IRBNet site. Login with your IRBNet Username and Password to authenticate your registration

 

To submit a NEW Project on IRBNet
  1. Go to http://www.irbnet.org and log in
  2. In the blue menu bar on the left hand side of the screen, choose Forms and Templates
  3. In the Library pull down menu, select University of Delaware IRB – Documents for Researchers
  4. From the list of documents in the library, download the University of Delaware Application Instructions if you are unfamiliar with the requirements or process
  5. Download the New project protocol form and save to your computer
  6. Fill out the Protocol form
  7. When you have all your study documents ready to submit

  8. Log back into IRBNet
  9. In blue menu bar on left-hand side of the page, choose Create New Project
  10. Fill out the online information (title, name, PI etc. Red * indicates required field) and click on the Continue button
  11. Click on the Add New Document button to upload your protocol form, consent form, surveys and questionnaires
  12. Choose Sign this Package from the blue menu bar on the left hand side of the screen to electronically sign the submission
  13. Choose Submit this Package from the same blue menu bar to submit the Project for IRB review
  14. Upon submission, you will receive an electronic notification via IRBNet.

 

To submit an Amendment, Continuing Review, or Adverse Event form on IRBNet
  1. Go to http://www.irbnet.org and log in
  2. In the blue menu bar on the left hand side of the screen, choose Forms and Templates
  3. From the Library pull down menu, select University of Delaware IRB – Documents for Researchers from the Library menu
  4. Download to your computer and fill out the relevant form
  5. When you have your documents ready to submit

  6. Log back into IRBNet
  7. In the blue menu bar on the left hand side of the screen, choose My Projects
  8. Click on the Project Title to select the Project for which you are making the additional submission
  9. Click on the Project History button on the left menu, then click on Create New Package box
  10. In the blue menu bar on the left hand side of the screen – click on Designer
  11. Click on the Add New Document box to upload your documents
  12. Choose Sign this Package from the blue menu bar on the left hand side of the screen to electronically sign the submission
  13. Choose Submit this Package from the same blue menu bar to submit the Project for IRB review
  14. Upon submission, you will receive an electronic notification on IRBNet.

Definitions

Clinical Trial

Exact definition of what type of studies constitute a clinical trial are different depending on the applicable oversight agency. More details on clinical trials can be found below.

Human subject

A living individual about whom an investigator (whether professional or student) conducting research obtains:

  • Data through intervention or interaction with the individual, or
  • Identifiable private information
Intervention

Includes both physical procedures by which data are gathered (for example, venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes.

Interaction

Includes communication or interpersonal contact between investigator and subject.

Minimal Risk

The probability and magnitude of of harms and sicomfort anticipated in the research are not greater than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

Private information

Includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). Private information must be individually identifiable (i.e., the identity of the subject is or may readily be ascertained by the investigator or associated with the information) in order for obtaining the information to constitute research involving human subjects.

Research

A systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.

 

Human Subjects: Review Types and Procedures

University of Delaware Institutional Review Board

The University of Delaware has one IRB registered with DHHS (IORG #0000279). UD IRB membership is in accordance with the applicable regulatory requirements in 45 CFR 46.107 and 21 CFR 56.107. IRB membership includes diverse backgrounds and expertise to promote adequate review of research commonly conducted by UD researchers. Membership shall include both scientists and non-scientists as well as outside community members. Members from the UD faculty and staff are to be nominated by their respective dean, department chair, or supervisor, in concurrence with the IRB Chair and the UD Vice President for Research, Scholarship, and Innovation. Outside community members (not affiliated with the UD community) will be nominated by the IRB Chair. The UD IRB members, including the IRB Chair, are appointed by the UD Vice President for Research, Scholarship and Innovation.

Members shall serve for terms of three years, renewable with concurrence of their respective dean, department chair, or supervisor, the IRB Chair and the UD Vice President for Research, Scholarship, and Innovation. All members will complete human subjects protections and IRB training prior to starting each term. Members are expected to attend regularly scheduled IRB meetings. 

IRB members may have designated alternate(s) members. An alternate is an individual appointed to the IRB to serve in the same capacity as the specific IRB member(s) for whom the alternate is named. Alternate members must meet the same training requirements as the full member for which they serve.

The UD IRB Office supports the functions of the IRB and its Chair, Dr. Jean-Philippe Laurenceau. The IRB can be contacted at:

University of Delaware IRB

210 Hullihen Hall (Research Office)

Phone: 302-831-2137

Email: hsrb-research@udel.edu

 


IRB Metings

UD IRB meetings are held monthly. Generally, meetings will be at noon on the third Wednesday of each month. Meeting dates and times are posted on the Research Office calendar of events. 

Research Office Calendar

For convened IRB meetings the required quorum is defined as more than half of the current full membership. At least one member whose primary concerns are in non-scientific areas, and one member whose primary concerns are in scientific areas must be in attendance to satisfy quorum requirements. In addition, if research involving prisoners is to be reviewed, the member designated as the prisoner advocate must also attend.

More

IRB members must avoid potential conflicts of interest when conducting protocol review. A potential conflict of interest occurs when a reasonable outside observer might perceive the circumstances as creating an apparent conflict of interest. Examples of such potential conflicts include an IRB member having a close personal relationship with a researcher submitting a proposal, an IRB member serving as a researcher on the proposed project, or an IRB member serving as a consultant to the project. IRB members with potential conflict of interest must recuse themselves and not be present for the discussion, except as to provide information requested by the IRB, and vote on the research. Recused members will not be counted towards the quorum requirements in the review and voting of the research for which they recused.

Quorum will be determined and verified by the IRB office staff member(s) attending the meeting before the discussion and vote for each item reviewed. IRB decisions will be made based on the vote of the majority of the eligible members present at the meeting. 

Participation in a convened meeting via tele or video conference is acceptable to meet quorum requirements provided the member(s) have received the materials to be reviewed prior to the meeting and can actively participate in the discussion.


Federalwide Assurance FWA

The University of Delaware has a Federalwide Assurance FWA (#00004379) on file with the Department of Health and Human Services (DHHS) Office for Human Research Protections (OHRP). Through this document the University commits itself to upholding the Code of Federal Regulations and the ethical principles of the Belmont Report for all research involving human subjects conducted by University faculty, staff, and students. The UD Vice President for Research, Scholarship and Innovation is the Signatory Official of the UD FWA.

For questions please contact the UD IRB Office or (302) 831-2137

 

There are six defined categories of research exempt from the regulatory requirements imposed by the “Common Rule’. Exempt review determinations MUST be made by the IRB office and require the submission of a research protocol to the IRB.

  1. Research conducted in established or commonly accepted educational settings, involving normal educational practices, such as
    (a) research on regular and special education instructional strategies, or
    (b) research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.
  2. Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior, unless
    (a) information obtained is recorded in such a manner that human subjects can be identified, directly or through identifiers linked to the subjects, AND
    (b) any disclosure of the human subjects’ responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects’ financial standing, employability, or reputation.

    Exemption 2 does not apply to children except for research involving observations of public behavior when the investigator does not participate in the activities being observed.

  3. Research involving the use of educational tests, survey procedures, interview procedures, or observation of public behavior that is not exempt under category 2, if
    (a) the human subjects are elected or appointed public officials or candidates for public office, or
    (b) federal statute(s) require(s) without exception that the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter.
  4. Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
  5. Research and demonstration projects that are conducted by or subject to the approval of department or agency heads and that are designed to study, evaluate, or otherwise examine
    (a) public benefit or service programs,
    (b) procedures for obtaining benefits or services under those programs,
    (c) possible changes in or alternatives to those programs or procedures, or
    (d) possible changes in methods or levels of payment for benefits or services under those programs.
  6. Taste and food quality evaluation and consumer acceptance studies,
    (a) if wholesome foods without additives are consumed, or
    (b) if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.

Exempt reviews are conducted as projects are submitted. Review times may vary depending on the overall volume of projects to be reviewed by the IRB at any given time. In most cases exempt reviews are completed within two weeks from the submission date. A project determined exempt does not require annual continuing reviews. Informed consent forms of projects determined to be exempt will not be stamped by the IRB. The IRB office should be consulted about proposed changes that could affect the exempt classification.

Expedited review procedures may be used for certain research activities described in the federal regulations. Expedited reviews are done by one or more experienced reviewers designated by the chairperson from among members of the IRB. Projects approved by the expedited review process are subject to the same regulatory requirements as those approved on a full board review and must be periodically reviewed by continuing review before the expiration date set on approval (no longer than one year since approval). Informed consent forms associated with projects reviewed by expedited review will be stamped by the IRB with the approval and expiration dates. IRB-stamped documents are posted in IRBNet after approval and must be used when obtaining the informed consent of research participants.

Protocols eligible for expedited review are evaluated on a rolling basis as they are submitted to IRBNet. Review times for expedited reviews vary depending on the total IRB submissions load at any given time and may take on average about two weeks from the time of complete submission.

  1. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
    (a) Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
    (b) Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.
  2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
    (a) from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or
    (b) from other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.
  3. Prospective collection of biological specimens for research purposes by noninvasive means. Examples:
    (a) hair and nail clippings in a nondisfiguring manner;
    (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;
    (c) permanent teeth if routine patient care indicates a need for extraction;
    (d) excreta and external secretions (including sweat);
    (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue;
    (f) placenta removed at delivery;

    (g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;
    (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques;
    (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;
    (j) sputum collected after saline mist nebulization.

  4. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.) Examples:
    (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject’s privacy;
    (b) weighing or testing sensory acuity;
    (c) magnetic resonance imaging;
    (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography;
    (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.
  5. Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis).
    (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(4). This listing refers only to research that is not exempt.)
  6. Collection of data from voice, video, digital, or image recordings made for research purposes.
  7. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies.
    (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3) . This listing refers only to research that is not exempt.)
  8. Continuing review of research previously approved by the convened IRB as follows:
    (a) where (i) the research is permanently closed to the enrollment of new subjects; (ii) all subjects have completed all research-related interventions; and (iii) the research remains active only for long-term follow-up of subjects; or
    (b) where no subjects have been enrolled and no additional risks have been identified; or
    (c) where the remaining research activities are limited to data analysis.
  9. Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

Review of non-exempt research that does not qualify for expedited review or that may present more than minimal risk to the subjects must be reviewed at a convened meeting of the University’s IRB. At the University of Delaware (UD) the IRB meets once every month and investigators proposing new protocols are usually invited to attend the IRB meeting to present their research and address any questions the Board members may have. Students having protocols reviewed at a convened meeting and presenting to the IRB must be accompanied by their faculty advisor.

The meeting dates for the IRB as well as the submission deadline for protocols to be considered for full board review at each month’s meeting are set well in advance and can be found in the Research Office Calendar of Events. The number of protocols to be reviewed at each meeting may be limited due the constraints of time and the complexity of other items on the agenda. Protocols will be accepted for review in the order received. If the board is not able to review a protocol in a particular month, it will be given priority for review in the following month.

Investigators submitting new projects are normally invited to attend the IRB meeting to present their project to the Board and answer any questions or concerns IRB Members may have. The results from the meeting are later communicated to the PI and any conditions the IRB may have set before approval can be effective will be addressed then. If a student-led new project is to be reviewed by the full board the academic advisor responsible for the student and project must accompany the student to the meeting.

Projects approved at a convened full board meeting must be periodically reviewed by continuing review before the expiration date set on approval and no less than once a year. Informed consent forms associated with projects reviewed at a full board will be stamped by the IRB with the approval and expiration dates. IRB-stamped documents are posted in IRBNet after approval and must be used when obtaining the informed consent of research participants.

In addition to the types of review listed above the IRB may provide administrative reviews when appropriate. Administrative reviews are used in cases in which the University of Delaware needs record of research with human subjects in which UD is engaged but for which review and approval are not issued by the UD IRB. This is the case, for example, when UD investigators are part of a research team performing research at another institution. Depending on the nature of the research and the collaboration arrangement, UD IRB may rely on the review and approval from the other institution’s IRB. UD keeps record of that reliance via an administrative review.

All UD investigators engaged in collaborative research with human subjects must consult with the UD IRB office and submit that proposed effort to the UD IRB regardless of other IRB reviews being sought after.

 

Human Subjects: Life Cycle and Data Management

Here is an overview of the Life Cyle of a IRB Protocol and Data Management.

All submissions for review of the UD IRB must be done via IRBNet. Forms and templates are available in IRBNet under the “Forms and Templates’ tab in the left-hand side menu options. All submissions must be signed-off by the principal investigator (PI) responsible for the project in IRBNet, and the student supervisor in the case of student-led projects. In addition, submissions should be shared as appropriate in IRBNet with other co-investigators and research team members to facilitate communication from the IRB office with the research team as well as access to IRB-approved documents.

Any research involving human subjects, bio specimens and/or tissue samples from humans, and/or private identifiable data must be reviewed by an Institutional Review Board (IRB). New project application packages must include:

  • the protocol form properly filled out
  • the informed consent/assent document(s) as Word documents,
  • and any other relevant materials (e.g., advertisements, research instruments, surveys, questionnaires, etc.). Additional documents should be uploaded as a compiled single PDF or Word document.

Once submitted the IRB office will determine the type of review needed. If the project is deemed to be exempt or suitable for an expedited review, the review will be the performed on an ongoing basis as the submission is received. Processing times will vary depending on the total workload of the IRB at a given time. When a new project is determined to require full board review it will be added to the next available IRB meeting agenda as it is received. The IRB at UD meets once a month and deadlines for submissions to be considered for review are posted in the research calendar. After review the IRB office will communicate with the principal investigator and request for any clarifications or edits needed to be completed before approval can be issued.

Once a review has been completed, decision letters are uploaded in IRBNet and always accessible to the investigator(s). Informed consent documents from projects approved via an expedited or full board reviewed will be stamped with the IRB approval and expiration date and also uploaded in IRBNet. Informed consent must be obtained using the stamped version of the approved documents, (i.e., participants signatures need to be collected in a copy of the stamped informed consent). No IRB stamp is added to informed consent documents associated to projects deemed to be exempt.


For questions, send email to: hsrb-research@udel.edu

If ANY changes need to be made to an IRB approved protocol, investigators must seek IRB approval of those changes prior to their implementation. Examples of changes that would require the submission of an approval are: changes to the research team members, modifications in the recruitment strategies and/or advertisement materials, any changes to the research instruments already approved, elimination of previously approved procedures and/or data collection measures, new approaches to data processing or storage, edits to the approved informed consent language, etc. Amendments are reviewed as they are submitted and may take on average up to 2 weeks to be completed.
Amendment submission packages must contain:

  • the amendment form properly filled out,
  • the tracked changes and clean versions of any documents affected by the amendment(e.g., edits to the previously approved protocol form and informed consent document, advertisement materials, etc.)Tracked changes version of any edited document must show all the markups including what is being added and/or removed.

If the amendment does affect the informed consent document, a clean version (changes accepted) needs to be submitted so a newly IRB-stamped informed consent can be issued upon approval. The approval of an amendment normally has no effect on the previously set expiration date.

Protocols approved by the IRB, whether under expedited or full board review, are required to undergo continuing review at least once per year, on or before the expiration date set at the time of approval for as long as recruitment and data collection is to take place, and/or private identifiable data is kept . The IRB may determine the need for more frequent review on a case by case basis. The IRB may request that the PI report back after a fixed period of time (e.g. 3 or 6 months) or after a specific number of participants have been enrolled or any other signpost chosen by the IRB. Expiration reminders are automatically sent from IRBNet to the Principal Investigator (PI) and all others with whom the project has been shared with, and granted full access to, in IRBNet. Reminders are sent 60 and 30 days before the project is set to expire. In addition an expiration alert is sent on the expiration day if no approval has been secured before that day. Applications for continuing review must be submitted with enough time to allow for IRB review prior to the expiration date. In order to maintain the expiration anniversary date continuing reviews applications are reviewed no earlier than 30 days before the expiration date (because of it, a 30 day expiration notice will always be received even when the application for review has been submitted before the 30 day prior to expiration). Once a continuing review is approved a new one year approval period starts and informed consent documents are stamped with the new expiration date.

Unless eligible for expedited continuing review, protocols originally reviewed and approved by the convened IRB meeting (full board) must undergo a full board continuing review. IRB meeting dates and deadlines must be considered when submitting a continuing application to be reviewed at a full board as to avoid lapses in IRB approval.
Continuing review submissions must contain:

  • the continuing review form properly filled in
  • all other current documents relevant to the project (at a minimum the most current previously approved protocol form and a clean version of the informed consent).
  • If any changes are proposed at the time of continuing review, the tracked changes version of all the affected documents needs to be added to the continuing review application.

Lapses in IRB Approval: It is the responsibility of the investigators to provide in a timely manner the information needed by the IRB to perform its continuing review functions. When continuing review of a research project is not completed prior to the end of the approval period specified, the IRB approval will expire. All research activities involving human subjects (i.e., participant recruitment and/or data collection), must stop after IRB approval expires and cannot be restarted until approval has been secured. Expired projects for which the IRB office has not been notified of the intent for continuation will be closed. Once closed, a project cannot be re-opened and will have to be resubmitted as ‘new’ for review and approval before any research related activities can be re-initiated.

Investigators must report to the IRB Office any instances of unanticipated problems (UP), and/or adverse events (AE) related to the research within 3 days of the incident.
Unanticipated problems, in general, include any incident, experience, or outcome that meets the following criteria:

  1. unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied;
  2. related or possibly related to participation in the research (in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research);
  3. suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

Adverse Events

An adverse event is any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (e.g.,, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research. Adverse events encompass both physical and psychological harms. They occur most commonly in the context of biomedical research, although on occasion, they can occur in the context of social and behavioral research.

Unanticipated problems and adverse events must be reported to the IRB by submitting the appropriate form via IRBNet. Depending on the nature and of the event reported and on a case by case basis the Director of Research Compliance and the IRB Chair will decide if review by the convened IRB of the submission is needed and when a for-casue audit of the research project may be required.

Depending on the outcome of an investigation and IRB review, an incident may have to be reported to the UD Signatory Official. The UD Signatory Official has the authority to decide if, as per the stipulated guidance, further reporting to OHRP and the funding agency is needed.

Suspensions / Terminations

The IRB has the authority to suspend or terminate IRB approval of research that is not being conducted in accordance with regulations or IRB requirements, or that has been associated with unexpected serious harm to subjects, or where suspension or termination had been initiated by an sponsored or other outside entity.
A suspension or termination of approval by the IRB will include a statement of the reason(s) for the IRB’s action and will be promptly reported to the investigator responsible for the project, the appropriate institutional officials, and to OHRP and other agencies as appropriate.
Reasons that could lead to the IRB’s suspension or termination of approval might include:

  • Inappropriate involvement of human subjects in research
  • Violation of the rights or welfare of research participants or others
  • Serious or continuing non-compliance with applicable regulations, IRB requirements, or institutional policies.
  • New Information regarding increased risk to research participants or others

Suspension for cause is a temporary stop by the IRB of some or all research procedures. The suspension report will state the reason(s) for the suspension and the required corrective measures to be applied before approval may be reinstated.

Termination for cause is a permanent revocation of IRB approval.

Auditing will be performed routinely by the IRB office staff to ascertain general compliance with the protection of human subjects requirements and IRB-approved protocol and procedures. In addition, for cause audits will be conducted as deemed appropriate by the Director of Research Compliance, and/or the IRB Chair to investigate reports of unanticipated problems, adverse events, and/or non-compliance.

  • Routine Audits: Projects are selected randomly among those active and approved via expedited and convened IRB review. The principal investigator responsible for the project is contacted to schedule a visit from the IRB office staff member conducting the audit. Prior to the scheduled visit the investigator is sent an outline of the review process. A report is generated after the audit and send to the investigator for review. Non-compliance and other findings resulting from a routine audit are shared with the IRB. If a non-compliance finding is determined by the IRB to be serious or continuing it will be further investigated and reported to the UD Signatory Official.
  • For cause Audit: adverse events and/or unanticipated problems involving risk to participants reported to the IRB office may be followed up with an investigation. For cause audits may also be performed to investigate non-compliance with IRB-approved protocols. Depending on the nature of the investigation for cause audits may be scheduled or unannounced. Reports from a for cause audit will be reviewed by the IRB. Depending on the outcome of a for cause audit and the IRB review of the report, an incident may have to be reported to the UD Signatory Official. The UD Signatory Official has the authority to decide if, as per the stipulated guidance, further reporting to OHRP and the funding agency is needed.

Protocols approved by the IRB under an expedited or full board review must receive continuing review at least once per year until closed. A project can be closed when all the following conditions are true:

  • Enrollment and all data collection for the study have been completed, private identifiable data is no longer being stored, accessed, or worked on,
  • the link (access code), if any, between the research data and the identifiers has been destroyed. More details on data storage and retention can be found here,

A closure submission should be done as soon as the conditions above are met by creating a new submission package in IRBNet and including the closure form. If no continuing review application nor closure request is submitted by the investigator, projects will be closed by the IRB Office upon expiration. Once a study has been closed it cannot be re-opened. Any future work related to the study (e.g., long- term follow up with participants, additional enrollment and data collection, etc.) will require for a new project to be reviewed and approved by the IRB before the work can start.

 

Human Subjects: Clinical Trials

Why is registration required?

Federal regulations and journal publications standards require that investigators register certain clinical studies in a publicly accessible database. www.ClinicalTrials.gov (CT.gov) was created to support compliance with those requirements and standards. The diagram below depicts the different requirements and how they, in some cases, may overlap.


Recruitment

FDAAANIHICMJE



  1. The FDA Amendments Act of 2007 (FDAAA) requires “Applicable Clinical Trials” involving drugs, biological products, and devices subject to the FDA regulations to be registered in ClinicalTrials.gov, regardless of the funding source for the study.
  2. The NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information (“NIH Policy”) is complementary to the reporting requirements of FDAAA and establishes the expectation that all investigators conducting clinical trials funded in whole or in part by the NIH will ensure that these trials are registered and that results submitted to ClinicalTrials.gov. .
  3. The International Committee of Medical Journal Editors (“ICMJE”) policy (adopted by over 1,000 journals) requires, and recommends that all medical journal editors require, registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication
  4. In addition, an investigator may voluntarily decide to register a study not subject to any of the requirements above (e.g., an observational study with no intervention assignment and not intended to be published in a ICMJE journal) as a way to publicly advertise the research (i.e., recruitment of research subjects). ClinicalTrials.gov supports and encourages the registration of all research studies with human subjects even if an explicit requirement does not apply.

For questions, send email to: clinicaltrials@udel.edu

What is a Clinical Trial?

The definition of clinical trial used is slightly different depending on the requirement:

  1. Per FDAAAApplicable Clinical Trials” generally include prospective interventional studies (with one or more arms) of FDA-regulated drugs, biological products, or devicesthat meet one or more of the following conditions (regardless of funding source):
    • The trial has one or more sites in the United States
    • The trial is conducted under an FDA investigational new drug application or investigational device exemption
    • The trial involves a drug, biologic, or device that is manufactured in the United States or its territories and is exported for research

    An interactive decision tool of the FDAAA applicable clinical trials definition is offered at https://grants.nih.gov/clinicaltrials_fdaaa/ACTs_under_FDAAA.htm enabling users to identify if the FDA requirements would apply to a specific study.
  2.  

  3. Per NIH a Clinical Trial is research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

    Recruitment

  4.  

  5. The ICMJE defines a clinical trial as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. Health-related interventions are those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes. Health outcomes are any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events.

For questions, send email to: clinicaltrials@udel.edu

I am the PI of a Clinical Trial. What do I do?

Once determined that a clinical trial will need to be registered in www.ClinicalTrials.gov the steps to follow are:

 

  1. If it is my first time registering a study: How do I obtain an account with ClinicalTrials.gov?

    Obtaining a username and password: If you do not have an account with ClinicalTrials.gov (i.e., no username and password), proceed to https://clinicaltrials.gov/:

    1. Click “Submit Studies”, and then click “How to apply for an account”.
    2. Towards the bottom of the page, click the link, “PRS Administrator Contact Request Form.” Complete the contact request form for the appropriate Organization (University of Delaware).
    3. You will receive an email from clinicaltrials.gov with the email address for the University of Delaware Protocol Registration System (PRS) Administrator account, clinicaltrials@udel.edu. Email the UD PRS Administrator account and request a username and password.
      University of Delaware has a PRS Administrator account – do not create PRS “individual account” when registering with ClinicalTrials.gov.
    4.  

    5. If you do not know if you have an account or have forgotten your username, use the same steps as above to verify your username.
  2.  

  3. How Do I Register a Trial?
    1. Prior to registration in ClinicalTrials.gov a UD research study must have received UD IRB approval. Pursuant to FDA Guidance, and NIH Policy the following exact statement must be included in the informed consent documents of studies to be registered in ClinicalTrials.gov:
      “A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time”

       

    2. Once a username and password has been obtained, proceed to the ClinicalTrials.gov “PRS Login Page”, enter the Organization (UDelaware), Username, and Password.
      For basic help with using PRS, review the “Quick Start Guide” and the “PRS User’s Guide” found in the “Help” section of the PRS top main menu, which is accessible after logging with your username and password.

       

    3. Complete all fields as to information related to the trial. Once all of the information has been entered in the PRS record, marked as complete, and released, an automated email will be sent to the UD PRS Administrator. Upon completion of the administrative review, which typically takes 3-5 business days, a UD PRS Administrator will approve and release the record to ClinicalTrials.gov, where the PRS team will review the record for quality control purposes prior to posting on the ClinicalTrials.gov website.
How do I Submit Trial Results?
  1. Enter Organization (UDelaware), your Username, and your Password on the “PRS Login Page
  2.  

  3. Update the “Protocol Section” and release (submit) the record

    a. Ensure that the information in the Protocol Section is up-to-date before starting the Results Section; e.g., overall recruitment status, study start date, primary and study completion dates, actual enrollment, and arm and intervention information.

    b. Begin results submission after the updated record has been published on ClinicalTrials.gov.

  4.  

  5. Enter the required and optional results data elements. Scientific information is submitted as four separate modules: the modules allow for the entry and display of information in a series of data tables with supporting notes, but without narrative conclusions about the results. The scientific information instructions section provides detailed information on how to prepare the submission of each module and it includes links to instructional online presentations:
    Participant FlowSummary of the progress of participants through each stage of a study, by study arm or comparison group. It includes the numbers of participants who started, completed, and dropped out of each period of the study based on the sequence in which interventions were assigned. The module accommodates a wide range of study designs and allows for the description of key events following study enrollment but prior to group assignment.
    Baseline CharacteristicsSummary of the data collected at the beginning of the study for all participants, by study arm or comparison group. These data include demographics, such as age and gender, and study-specific measures (e.g., systolic blood pressure prior to exercise treatment).
    Outcome Measures and Statistical AnalysesSummary of outcome measure values, by study arm or comparison group. It includes tables for each prespecified Primary Outcome and Secondary Outcome and may also include other prespecified outcomes, post hoc outcomes, and appropriate statistical analyses.
    Adverse EventsSummary of all anticipated and unanticipated serious adverse events and a tabular summary of anticipated and unanticipated other adverse events exceeding a specific frequency threshold.
  6.  

  7. Preview, inspect, and release (submit) the record. For a description of criteria that should be addressed before releasing (submitting) the record, see “ClinicalTrials.gov Results Review Criteria
  8.  

  9. When the record is released, an automated email will be sent to the UD PRS Administrator. Upon completion of the administrative review, which typically takes 3-5 business days, the UD PRS Administrator will approve and release the record to ClinicalTrials.gov, where a ClinicalTrials.gov staff member will review the record for quality control purposes prior to posting the results on the ClinicalTrials.gov website
  10.  

  11. Resources for the submission of results:

    a.Basic Results Data Element Definitions”, contains descriptions of each required data item.

    b. Results data preparation checklists, simple results templates for each module, required data, and a view of data elements in a tabular form are listed in the “Scientific Information” section of the “How to Submit Your Results” guidance on ClinicalTrials.gov.

    c. Helpful Hints” contains tips on entering results data, including three examples of common study models (parallel design, crossover design, and diagnostic accuracy studies) and measure types.

 


For questions, send email to: clinicaltrials@udel.edu

Additional Information
  1. ClinicalTrials.Gov – Introduction to Requirements and Registration Procedures
    1. ClinicalTrials.gov is a searchable web database of clinical studies of human participants. The website is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).
  2. There is a link at the bottom of each page on clinicaltrials.gov to submit a ticket for help: “CONTACT NLM HELP DESK”.
  3.  

  4. ClinicalTrials.gov may be contacted with questions or for guidance via email at register@clinicaltrials.gov.
    1. If the question is about a specific study record, please provide the NCT Number or the Unique Protocol ID (if an NCT Number has not yet been assigned).
    2. Be detailed in your request. ClinicalTrials.gov generally responds to all emails within 1 business day.

 

Please see ClinicalTrials.Gov Guidance & Procedures here.


For questions, send email to: clinicaltrials@udel.edu

Training

Training in the protection of human subjects in research is required for all university members (i.e., faculty, students, researchers, and staff), and collaborators, who will directly interact with research participants or have access to identifiable private information. Training in human subjects protections (HSP) must be completed, and the completion report obtained, prior to seeking review and approval from the IRB to conduct research. 

Research Office Calendar
More

In addition to the required training in human subjects protections, and as per NIH policy, training in Good Clinical Practice (GCP) must also be completed by all research team members involved in NIH-supported clinical trials. NIH defines a clinical trial as any research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

All personnel actively engaged in human subjects research must maintain current training by completing the

required courses every three (3) years. Training is available, and must be completed, online through the Collaborative Institutional Training Initiative (CITI) Program. Principal Investigators submitting a research proposal for review to the IRB are responsible for ensuring all researchers to be engaged in human subjects research under his/her supervision hold valid and current training certifications. If researchers have not linked their training certification to their user profile in IRBNet, certifications of training completion for all research.

 

HIPAA

In the context of research, the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule establishes the conditions under which protected health information (PHI) may be used or disclosed by covered entities for research purposes. The Privacy Rule protects the privacy of individually identifiable health information, while at the same time ensuring that researchers continue to have access to medical information necessary to conduct research.
How the Rule Works:

Under HIPAA, researchers may obtain, create, use, disclose and/or otherwise access PHI for research purposes through one of the following methods:

  • By obtaining individual authorization: An Authorization is basically an individual’s written permission or consent to use his or her PHI for research purposes. HIPAA requires that an Authorization be written in plain language and contain certain “core” elements. Research authorizations may be combined with an informed consent form or set forth in a separate Authorization document. See forms and templates in IRBNet for further guidance on what to include in a HIPAA Authorization for research.
  • By obtaining IRB waiver or alteration of the authorization requirement: The following three criteria must be satisfied for an IRB or Privacy Board to approve a waiver of authorization under the Privacy Rule: 
    1. The use or disclosure of protected health information involves no more than a minimal risk to the privacy of individuals, based on, at least, the presence of the following elements: 
      • an adequate plan to protect the identifiers from improper use and disclosure; 
      • an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law; and 
      • adequate written assurances that the protected health information will not be reused or disclosed to any other person or entity, except as permitted by this subpart; 
    2. The research could not practicably be conducted without the waiver or alteration; and 
    3. The research could not practicably be conducted without access to and use of the protected health information. 
  • By using de-identified information: Health information that has been “de-identified” in a manner required by HIPAA is not considered PHI and may be used or disclosed for research purposes without individual authorization. De-identification can be done by removal of all 18 elements that could be used to identify an individual and/or the individual’s relatives as described in the Privacy Rule. Alternatively, de-identification may be established by the use of statistical methods.
  • By using limited data sets with a data use agreement: A limited data set is described as health information that excludes certain, listed direct identifiers but that may include city; state; ZIP Code; elements of date; and other numbers, characteristics, or codes not listed as direct identifiers. It is the responsibility of the researcher and the party releasing the PHI to have in place and maintain a copy of a data use agreement that meets HIPAA requirements.
  • By using only decedents’ information, with certain assurances
  • By using PHI for purposes preparatory to research, with certain assurances and with no removal of any PHI from the covered entity (physically or electronically)

 

ASSISTANCE

Compliance Hotline
Phone: (302) 831-2792

E: UD IRB Office
P: (302) 831-2137
F: (302) 831-2828

HUMAN SUBJECT LINKS

UD Policy & Procedure Manual
Involvement of Human Subjects in Research and Research-Related Activities

Belmont Report
Ethical principles for the protection of human subjects in research.

Common Rule
The Federal Policy for the Protection of Human Subjects or the “Common Rule” was published in 1991 and codified in separate regulations by 15 Federal departments and agencies, as listed here.

Office of Human Research Protections (OHRP)
United States Department of Health & Human Services Information

FDA Regulations relating to GCP and Clinical Trials

UD Research Administration

Conducting Research

Responsible Conduct of Research

Ensuring the responsible conduct of research is of paramount importance to the University of Delaware and to the nation.

""Compliance Hotline
""F.A.Q.
""Roles and Responsibilities

“Scientific research is grounded in values such as integrity, honesty, trust, curiosity, and respect for intellectual achievement. The expression of these values in the diverse styles and approaches of the various scientific disciplines has contributed directly to the discovery of knowledge and thus to the achievements of the U.S. scientific research enterprise,” noted the National Academy of Sciences’ Committee on Science, Engineering, and Public Policy in the report, On Being a Scientist: Responsible Conduct in Research.

However, as the report goes on to say, growth of the U.S. research enterprise,changing social expectations about the accountability of scientists, increasingly complex research that places new demands on scientific oversight, and expanded commercialization of research results have catalyzed the formation and implementation of new policies and regulations by academic institutions and funding agencies to safeguard the process of science in today’s academic research arena.

The University of Delaware holds its faculty and staff to the highes standards of conduct. It is University policy that “employees are expected at all times, to respect the rights of the University, its students, visitors and other members of the University community. Inherent in this responsibility is the obligation to be courteous, respectful, honest, and to protect the University environment.”

These standards of conduct are critical to every step of the UD researcher’s pursuit of the truth — from the formulation of proposals, to interactions with research associates and students, to the collection and handling of data from experiments or other scholarly activity, to the evaluation of that data, peer review, and protection and presentation of results. Furthermore, research involving human or animal subjects must be administered according to established University policies and federal regulations and with a commitment to the highest ethical standards.

Every UD researcher needs to understand and comply with the policies and procedures, established by the University and the federal government, that are relevant to his or her research. You’ll find links to a complete listing of UD’s policies, along with required forms, highlighted in the blue box above and on our Policies & Forms page on this Web site.

Additional Resources
  • On Being a Scientist: Responsible Conduct in Research. (Committee on Science, Engineering, and Public Policy, National Academy of Sciences, National Academy Press, 1995).
  • Responsible Conduct of Research Education Committee.Part of the Association for Practical and Professional Ethics, this committee provides leadership to the research community in identifying and developing education programs in the responsible conduct of research.
  • Responsible Conduct Courses. This Web site, produced by Columbia University with support from the Department of Health and Human Services, presents case studies on conflicts of interest, mentoring, peer review, misconduct, and data management.
  • UD’s Science, Ethics, and Public Policy Program (SEPP). This new program’s purpose is to integrate ethics and public policy inquiry with scientific research, University curricula, private sector innovation, and government policy-making. SEPP seeks to clarify questions of fact and value of pressing concern in scientific research; to enhance the dialogue among academic, corporate, and public-interest stakeholders; to increase the synergies of public-private cooperation in emerging technologies where there are significant ethical concerns; and ultimately to establish in Delaware a unique center of national excellence to serve the public good.
ASSISTANCE

Compliance Hotline
Phone: (302) 831-2792

UD Research Office
210 Hullihen Hall
Newark, DE 19716
Phone: (302) 831-2136
Fax: (302) 831-2828
Contact us

SUBSCRIBE & CONNECT

From our latest Research Magazine to our latest discoveries, keep in touch with UD Research by signing up for our services below.

Share This